Clinical trials
Withdrawn Neoplasms trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
331 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 2 |
| 2001 | 1 |
| 2003 | 2 |
| 2004 | 2 |
| 2005 | 5 |
| 2006 | 10 |
| 2007 | 10 |
| 2008 | 10 |
| 2009 | 10 |
| 2010 | 15 |
| 2011 | 10 |
| 2012 | 11 |
| 2013 | 16 |
| 2014 | 24 |
| 2015 | 14 |
| 2016 | 15 |
| 2017 | 24 |
| 2018 | 15 |
| 2019 | 20 |
| 2020 | 17 |
| 2021 | 10 |
| 2022 | 15 |
| 2023 | 16 |
| 2024 | 24 |
| 2025 | 13 |
| 2026 | 6 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Withdrawn | 331 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 12 |
| GlaxoSmithKline | 9 |
| M.D. Anderson Cancer Center | 8 |
| Washington University School of Medicine | 5 |
| AbbVie | 4 |
| Case Comprehensive Cancer Center | 4 |
| Emory University | 4 |
| Johns Hopkins University | 4 |
| Stanford University | 4 |
| Assistance Publique - Hôpitaux de Paris | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Neoplasms | 331 |
| Neoplasm Metastasis | 19 |
| Pancreatic Neoplasms | 18 |
| Breast Neoplasms | 15 |
| Recurrence | 15 |
| Carcinoma, Non-Small-Cell Lung | 13 |
| Pain | 13 |
| Lung Neoplasms | 11 |
| Prostatic Neoplasms | 10 |
| Brain Neoplasms | 9 |
Trials
Showing 76 to 100 of 331. Each trial links to its page on Pharma Observatory.
231 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.